Bovine-lactoferrin/hypothiocyanite - Alaxia

Drug Profile

Bovine-lactoferrin/hypothiocyanite - Alaxia

Alternative Names: ALX 009

Latest Information Update: 18 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alaxia
  • Class Anions; Antibacterials; Glycoproteins; Iron binding proteins
  • Mechanism of Action Cell membrane modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 20 Nov 2015 Alaxia plans a phase I trial for Cystic Fibrosis in France (NCT02598999)
  • 01 Nov 2015 Phase-I clinical trials in Cystic fibrosis in France (Inhalation)
  • 01 Jan 2012 Preclinical trials in Cystic fibrosis in France (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top